Biotech Values

[DewDiligence]

>> It is an interesting article, but it is decidedly one-sided. It would have been nice if strong proponents of the amyloid these were, at least, allowed to answer the criticisms of their position. <<

Good point. In case you missed it, here’s a NY Times article on AD which better represents the “amyloid mainstream”: #msg-2836718.

And here’s another NY Times article that was strongly critical of existing AD drugs: #msg-2797088. Dew